Serina Therapeutics Q3 net loss widens on higher R&D costs
SER•Serina Therapeutics reported Q3 revenue of $125,000, up from zero a year earlier, while its net loss widened to $7.9 million from $4.7 million. The company advanced its SER-252 Parkinson’s study to Cohort 2 and expects topline single-ascending-dose data in the first half of 2027.
1. Quarterly results
Serina Therapeutics reported Q3 revenue of $125,000, compared with zero a year earlier. Its net loss widened to $7.9 million from $4.7 million as research and development and general and administrative expenses increased. Higher R&D costs reflected clinical activities, contract manufacturing and compensation.
2. SER-252 study
The company advanced its SER-252 Parkinson’s disease study to Cohort 2 after an independent safety review and continues dosing patients in the cohort. Initial blinded Cohort 1 observations showed pharmacokinetic findings consistent with intended prolonged drug exposure and some improvement in motor function in individual patients. Serina expects topline single-ascending-dose data in the first half of 2027.
